Chabiotech Co.,Ltd. (KOSDAQ:085660)

South Korea · Delayed Price · Currency is KRW

6,800.00

+50.00 (0.74%)

Nov 2, 2026, 3:30 PM KST

Market Cap	629.02B -33.8%
Revenue (ttm)	1.31T +13.9%
Net Income	14.27B
EPS	11.70
Shares Out	92.50M
PE Ratio	581.17
Forward PE	n/a
Dividend	n/a
Ex-Dividend Date	n/a

Volume	117,818
Open	6,690.00
Previous Close	6,750.00
Day's Range	6,560.00 - 6,850.00
52-Week Range	6,560.00 - 23,950.00
Beta	0.62
Analysts	n/a
Price Target	n/a
Est. Earnings	Nov 13, 2026

About Chabiotech

Chabiotech Co.,Ltd., a bio company, develops cell and gene therapy related to stem and immune cells in South Korea and internationally. The company provides an umbilical cord blood consignment storage for the treatment of incurable diseases; regenerative medicines, immune cell and stem cell storage services, anti-aging, and solutions for incurable diseases; medical wellness programs, comprising fitness, spa, and scupplements; and customized development, production, clinical, and commercialization services to customers with research and developm... [Read more]

Industry Biotechnology

Sector Healthcare

Founded 2002

Employees 296

Stock Exchange KOSDAQ

Ticker Symbol 085660

Full Company Profile

Financial Performance

In 2025, Chabiotech's revenue was 1.27 trillion, an increase of 21.36% compared to the previous year's 1.05 trillion. Losses were -109.88 billion, 2206.6% more than in 2024.

Financial Statements